Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy
Globe Newswire•24/08/2026•08:00 ET
0
Whiz Insights
Get started
Create a free account to read the full story.